What is the CVR number of 1stDrugResearch ApS?

1stDrugResearch ApS is registered with CVR / Virk under CVR 40927697.

What is the revenue of 1stDrugResearch ApS?

1stDrugResearch ApS reported revenue of DKK -11K in 2020.

Who is the chairman of 1stDrugResearch ApS?

Bo Dencker Sørensen chairs the board of 1stDrugResearch ApS, in role since 2019.

Where is 1stDrugResearch ApS headquartered?

1stDrugResearch ApS's registered address is Bytoften 2E.

1stDrugResearch ApS

APSDissolved

CVR 40927697Bytoften 2EManufacture of pharmaceutical preparations · NACE 2120Est. 2019— employees

Full Risika report

Revenue 2020

DKK -11K

-112% vs 2019

EBITDA margin

100.0%

-112% vs 2019

Equity ratio

73.9%

Financial strength

Net profit 2020

DKK -10K

-114% vs 2019

EBITDA — year on yearDKK millions

Key figuresAnnual report 2020

Revenue	DKK -11K	-112%
EBITDA	DKK -11K	-112%
Net profit	DKK -10K	-114%
Total assets	DKK 143K	-30%
Equity	DKK 106K	-9%
Employees	—	—

Item	2019	2020
Revenue	99	-11
Staff expenses	-0	-0
EBITDA	99	-11
Depreciation & amort.	-0	-0
EBIT	99	-11
Net financials	0	-1
Profit before tax	99	-13
Tax	23	-2
Net profit	76	-10

Item	2019	2020
Total assets	204	143
Equity	116	106
Long-term debt	0	0
Short-term debt	88	37
Total debt	88	37

Name	Role	Member since	Age	Other directorships
BD Bo Dencker Sørensen	Chairman	2019	—	—

Shareholder	Type	Ownership	Votes	Since
DENCKER GRUPPEN ApS	Company	50.0%	50.0%	2019
Ole Winther Rasmussen	Individual	50.0%	50.0%	2019

Person	Role here	Other companies
Bo Dencker Sørensen	Chairman	0 companies

1stDrugResearch ApS

APSDissolved

CVR 40927697Bytoften 2EManufacture of pharmaceutical preparations · NACE 2120Est. 2019— employees

Full Risika report

Revenue 2020

DKK -11K

-112% vs 2019

EBITDA margin

100.0%

-112% vs 2019

Equity ratio

73.9%

Financial strength

Net profit 2020

DKK -10K

-114% vs 2019

EBITDA — year on yearDKK millions

Key figuresAnnual report 2020

Revenue	DKK -11K	-112%
EBITDA	DKK -11K	-112%
Net profit	DKK -10K	-114%
Total assets	DKK 143K	-30%
Equity	DKK 106K	-9%
Employees	—	—